Tirzepatide, CAVI, and arterial stiffness

A retrospective cohort study published in Obesity Pillars in June 2026 found that tirzepatide significantly reduced a key measure of arterial stiffness in adults with obesity and type 2 diabetes, alongside improvements in body weight and glycaemic control^[1]. The measure used was the cardio-ankle vascular index (CAVI), a blood-pressure-independent marker of artery stiffness that runs from the aortic root to the ankle.

What is CAVI and why does it matter

CAVI was developed to capture the overall stiffness of the arterial tree independent of blood pressure at the moment of measurement, a limitation that affects older indices such as pulse wave velocity^[2]. Higher CAVI values indicate stiffer arteries and have been associated with coronary artery disease, chronic kidney disease, and cerebrovascular disease. A widely cited threshold places CAVI below 8.0 as normal, 8.0 to below 9.0 as borderline, and 9.0 or above as abnormal, with values at or above 9.0 proposed as an optimal cut-off for predicting cardiovascular events^[3].

Because arterial stiffness is a modifiable intermediate, clinicians and researchers track CAVI to gauge whether an intervention is affecting vascular health beyond its effects on conventional metabolic markers. It responds to diabetes and hypertension control and to smoking cessation, making it a useful endpoint when studying cardiometabolic treatments.

Study design and participants

The Japanese study enrolled 24 adults (45.8% male, median age 48.6 years, median BMI 32.3 kg/m2) with obesity plus type 2 diabetes. All received weekly tirzepatide at doses ranging from 5 to 15 mg over a median treatment duration of 12.7 months. Two-thirds of the cohort (66.7%) had previously been treated with a GLP-1 receptor agonist before switching to tirzepatide^[1]. This real-world Japanese cohort pattern is consistent with earlier real-world tirzepatide data from Japan.

The retrospective design means the investigators analysed existing clinical records rather than randomising participants to different treatments. As a result, the study can identify associations but cannot establish causation with the same confidence a randomised controlled trial would provide. The authors acknowledge this limitation explicitly.

Key findings

CAVI fell significantly from a median of 8.5 at baseline to 7.8 after treatment, crossing from the borderline range into the normal range based on published thresholds^[1]. Alongside this, median BMI dropped from 33.8 to 31.8 kg/m2, and median HbA1c improved from 6.6% to 5.6%. The urinary albumin-to-creatinine ratio (UACR), a marker of early kidney injury, trended downward from 11.9 to 7.2 mg/gCr, though this did not reach conventional significance (p = 0.067).

A dose-response pattern emerged in the weight data: participants receiving the higher doses of 10 to 15 mg showed greater BMI reduction than those on lower doses (p = 0.040). The CAVI reduction also tended to be larger at higher doses, though that comparison did not reach significance (p = 0.089)^[1]. Baseline skeletal muscle index was negatively correlated with the change in CAVI (rs = -0.424), suggesting that individuals with more muscle at the start showed smaller reductions in arterial stiffness, possibly because they had less vascular injury to reverse.

Prior use of a GLP-1 receptor agonist before switching to tirzepatide did not appear to affect outcomes, which the authors interpret as consistent with tirzepatide offering additive vascular benefit through its dual GIP receptor activity beyond what single-pathway GLP-1 agonism provides.

Tirzepatide's dual mechanism and vascular biology

Tirzepatide activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Reviews of the incretin class describe how GLP-1 and GIP exert complementary metabolic and vascular effects, with GLP-1 receptor agonists showing reductions in blood pressure, favourable changes in lipid profiles, suppression of systemic inflammatory markers, and improvements in endothelial function^[4]. Tirzepatide's dual action is hypothesised to amplify these vascular effects through greater reductions in visceral adiposity, which is a driver of endothelial dysfunction.

The authors of the Obesity Pillars study suggest the CAVI reduction seen in their cohort likely reflects a combination of weight loss, improved glycaemic control, and possible direct vascular effects of tirzepatide. They note that body composition monitoring is warranted given the simultaneous reduction in skeletal muscle index alongside fat loss, as preserving muscle is important for long-term metabolic and functional health.

Limitations and what we do not yet know

The study's sample size of 24 is small, the design is retrospective, and there is no placebo or comparator arm. Without randomisation it is not possible to determine how much of the CAVI improvement was attributable to tirzepatide specifically versus the natural course of weight loss, improved glycaemic control achieved by any means, or regression to the mean. The cohort was entirely Japanese, and whether the findings extend to other ethnic and metabolic backgrounds is not established.

Larger, prospective trials with longer follow-up and active comparators are needed to confirm whether tirzepatide produces a clinically meaningful reduction in arterial stiffness beyond what matched weight loss from other interventions would achieve, and whether that translates into reduced rates of cardiovascular events. The dedicated tirzepatide cardiovascular outcomes trial in people with obesity without diabetes has not yet reported.

What this means for readers

This study adds to the body of evidence suggesting that tirzepatide may have benefits for vascular health beyond its effects on glucose and body weight. The CAVI reduction from borderline to normal range is a noteworthy signal, but it comes from a small retrospective cohort and should be interpreted cautiously until confirmed in larger trials. Readers seeking the full evidence base for tirzepatide including its SURMOUNT and SURPASS trial data, approved indications, and regulatory status by country can find that information on the tirzepatide page on this site. For context on where tirzepatide sits in current prescribing frameworks, the ACP first-line obesity guideline sets out the current US recommendation hierarchy. This article summarises a single research publication and does not constitute medical advice. Any decision about treatment should be made in consultation with a qualified clinician.